Einer der führender Wissenschaftler in der Aspirin-Forschung präsentiert erstmals umfassend die Geschichte, pharmakologische Wirkung und klinische Anwendung eines der erfolgreichsten Medikamente. Schrör wendet sich mit seinem Buch an ein breites Publikum und bereitet das Thema für Klinikärzte, Forscher im Bereich Biomedizin und Pharmakologen in verständlicher Form auf. Das aktuelle Kompendium enthält die neuesten Erkenntnissen klinischer und akademischer Forschung und beleuchtet die umstrittenen Eigenschaften dieses populären Medikaments, ohne Partei zu ergreifen.
Einer der führender Wissenschaftler in der Aspirin-Forschung präsentiert erstmals umfassend die Geschichte, pharmakologische Wirkung und klinische Anwendung eines der erfolgreichsten Medikamente. Schrör wendet sich mit seinem Buch an ein breites Publikum und bereitet das Thema für Klinikärzte, Forscher im Bereich Biomedizin und Pharmakologen in verständlicher Form auf. Das aktuelle Kompendium enthält die neuesten Erkenntnissen klinischer und akademischer Forschung und beleuchtet die umstrittenen Eigenschaften dieses populären Medikaments, ohne Partei zu ergreifen.
Prof. Karsten Schrör, MD Institut für Pharmakologie und Klinische Pharmakologie Heinrich-Heine-Universität Düsseldorf
CURRICULUM VITAE (May, 2008)
Date of birth: May 3, 1942
Place of birth: Oldenburg
Marital status: married
Education: 1961 - 1967 Medicine, Universität Halle/Wittenberg 1967 - 1972 Pharmacology, Universität Halle/Wittenberg
MD Thesis: Effects of variations in external Ca++- and K+-concentrations on sympathetic nerve stimulation (Department of Physiology, Universität Halle/Wittenberg, 1970)
Wellcome Research Laboratories (UK); Supervisor: Sir John R. Vane, 1976 - 1977; Department of Physiology, Jefferson Medical College, Philadelphia (USA); Supervisor: Prof. A.M. Lefer, 1977; Visiting Professor at the Medical University of South Carolina at Charleston (USA) (Prof. P.V. Halushka), 1993 - 1994; Visiting Professor at the Department of Internal Medicine, Division of Hematology
Inhaltsangabe
TABLE OF CONTENTS1. GENERAL ASPECTS1.1 HISTORY1.1.1 WILLOW BARK AND LEAVES AS ANTIPYRETIC, ANTI-INFLAMMATORY ANALGESICS1.1.2 SALICYLATES AS THE ACTIVE INGREDIENT OF WILLOW BARK AND OTHER NATURAL SOURCES1.1.3 SYNTHESIS OF ACETYLSALICYLIC ACID AND FIRST CLINICAL STUDIES1.1.4 MODE OF ASPIRIN ACTION1.1.5 ANTI-INFLAMMATORY/ANALGESIC ACTIONS OF ASPIRIN1.1.6 ASPIRIN IN THE CARDIOVASCULAR SYSTEM1.1.7 CURRENT RESEARCH TOPICS1.2 CHEMISTRY1.2.1 STRUCTURES AND CHEMICAL PROPERTIES OF SALICYLATES1.2.2 DETERMINATION OF SALICYLATES2. PHARMACOLOGY2.1 PHARMACOKINETICS2.1.1 ABSORPTION AND DISTRIBUTION2.1.2 BIOTRANSFORMATION AND EXCRETION2.2 CELLULAR MODES OF ACTION2.2.1 INHIBITION OF CYCLOOXYGENASES2.2.2 COX-INDEPENDENT ACTIONS ON CELL FUNCTION2.2.3 ENERGY METABOLISM2.3 ACTIONS ON ORGANS AND TISSUES2.3.1 HEMOSTASIS AND THROMBOSIS2.3.2 INFLAMMATION, PAIN AND FEVER2.3.3 ASPIRIN AND MALIGNANCIES3. TOXICITY AND DRUG SAFETY3.1 SYSTEMIC SIDE-EFFECTS3.1.1 ACUTE AND CHRONIC TOXICITY3.1.2 BLEEDING DISORDERS3.1.3 SAFETY PHARMACOLOGY IN PARTICULAR LIFE SITUATIONS3.2 ORGAN TOXICITY3.2.1 GASTROINTESTINAL (GI) TRACT3.2.2 KIDNEY3.2.3 LIVER3.2.4 AUDIOVESTIBULAR SYSTEM3.3 NON-DOSE-RELATED (PSEUDO)ALLERGIC ACTIONS OF ASPIRIN3.3.1 ASPIRIN HYPERSENSITIVITY (WIDAL'S SYNDROME)3.3.2 URTICARIA/ANGIOEDEMA, STEVENS-JOHNSON- AND LYELL-SYNDROME3.3.3 REYE SYNDROME4. CLINICAL APPLICATIONS OF ASPIRIN4.1 THROMBOEMBOLIC DISEASES4.1.1 CORONARY VASCULAR DISEASE4.1.2 CEREBROVASCULAR DISEASES4.1.3 PERIPHERAL ARTERIAL DISEASE (PAD)4.1.4 VENOUS THROMBOSIS4.1.5 PREECLAMPSIA4.1.6 ASPIRIN "RESISTANCE"4.2 PAIN, FEVER AND INFLAMMATORY DISEASES4.2.1 ASPIRIN AS AN ANTIPYRETIC ANALGESIC4.2.2 ARTHRITIS AND RHEUMATISM4.2.3 KAWASAKI DISEASE4.3 FURTHER CLINICAL INDICATIONS4.3.1 COLORECTAL CANCER4.3.2 ALZHEIMER DISEASEABBREVIATIONS (NO ACRONYMS FOR CLINICAL STUDIES)ACRONYMS FOR CLINICAL STUDIESINDEX TERMS (PRELIMINARY)
TABLE OF CONTENTS1. GENERAL ASPECTS1.1 HISTORY1.1.1 WILLOW BARK AND LEAVES AS ANTIPYRETIC, ANTI-INFLAMMATORY ANALGESICS1.1.2 SALICYLATES AS THE ACTIVE INGREDIENT OF WILLOW BARK AND OTHER NATURAL SOURCES1.1.3 SYNTHESIS OF ACETYLSALICYLIC ACID AND FIRST CLINICAL STUDIES1.1.4 MODE OF ASPIRIN ACTION1.1.5 ANTI-INFLAMMATORY/ANALGESIC ACTIONS OF ASPIRIN1.1.6 ASPIRIN IN THE CARDIOVASCULAR SYSTEM1.1.7 CURRENT RESEARCH TOPICS1.2 CHEMISTRY1.2.1 STRUCTURES AND CHEMICAL PROPERTIES OF SALICYLATES1.2.2 DETERMINATION OF SALICYLATES2. PHARMACOLOGY2.1 PHARMACOKINETICS2.1.1 ABSORPTION AND DISTRIBUTION2.1.2 BIOTRANSFORMATION AND EXCRETION2.2 CELLULAR MODES OF ACTION2.2.1 INHIBITION OF CYCLOOXYGENASES2.2.2 COX-INDEPENDENT ACTIONS ON CELL FUNCTION2.2.3 ENERGY METABOLISM2.3 ACTIONS ON ORGANS AND TISSUES2.3.1 HEMOSTASIS AND THROMBOSIS2.3.2 INFLAMMATION, PAIN AND FEVER2.3.3 ASPIRIN AND MALIGNANCIES3. TOXICITY AND DRUG SAFETY3.1 SYSTEMIC SIDE-EFFECTS3.1.1 ACUTE AND CHRONIC TOXICITY3.1.2 BLEEDING DISORDERS3.1.3 SAFETY PHARMACOLOGY IN PARTICULAR LIFE SITUATIONS3.2 ORGAN TOXICITY3.2.1 GASTROINTESTINAL (GI) TRACT3.2.2 KIDNEY3.2.3 LIVER3.2.4 AUDIOVESTIBULAR SYSTEM3.3 NON-DOSE-RELATED (PSEUDO)ALLERGIC ACTIONS OF ASPIRIN3.3.1 ASPIRIN HYPERSENSITIVITY (WIDAL'S SYNDROME)3.3.2 URTICARIA/ANGIOEDEMA, STEVENS-JOHNSON- AND LYELL-SYNDROME3.3.3 REYE SYNDROME4. CLINICAL APPLICATIONS OF ASPIRIN4.1 THROMBOEMBOLIC DISEASES4.1.1 CORONARY VASCULAR DISEASE4.1.2 CEREBROVASCULAR DISEASES4.1.3 PERIPHERAL ARTERIAL DISEASE (PAD)4.1.4 VENOUS THROMBOSIS4.1.5 PREECLAMPSIA4.1.6 ASPIRIN "RESISTANCE"4.2 PAIN, FEVER AND INFLAMMATORY DISEASES4.2.1 ASPIRIN AS AN ANTIPYRETIC ANALGESIC4.2.2 ARTHRITIS AND RHEUMATISM4.2.3 KAWASAKI DISEASE4.3 FURTHER CLINICAL INDICATIONS4.3.1 COLORECTAL CANCER4.3.2 ALZHEIMER DISEASEABBREVIATIONS (NO ACRONYMS FOR CLINICAL STUDIES)ACRONYMS FOR CLINICAL STUDIESINDEX TERMS (PRELIMINARY)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
